South Korean biotech company Celltrion Group pursues the COVID-19 therapy market with the recent announcement of pre-clinical results for regdanvimab (CT-P59), a monoclonal antibody treatment…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.